R01CA266223
Project Grant
Overview
Grant Description
ALOX15 Regulation of Colon Cancer Invasiveness via PI3P-Linoleic Acid Metabolism
Colorectal cancer (CRC) is the third leading cause of cancer deaths in the United States. The long-term goal of our research is to develop novel interventions to prevent colorectal carcinogenesis (CRC). CRC invasiveness, a critical adverse step during CRC progression, requires a combination of certain genetic mutations (e.g. APC, KRAS, and TRP53 mutations), which are the key events to drive CRC. However, CRC progression also requires additional factors which increase aberrant beta-catenin (B-catenin) activation above levels induced by APC/B-catenin mutations.
Linoleic acid (LA), the most commonly consumed omega-6 polyunsaturated fatty acid in humans, increases both chemically (AOM)- and APC mutation-induced CRC tumorigenesis in mice. Nonetheless, human studies have been inconclusive regarding the impact of dietary LA on CRC. Determination of LA's role in CRC is important because American diets are enriched with LA while expression of the main metabolizing enzyme for LA, 15-lipoxygenase-1 (ALOX15), is lost in human CRC.
Recently, we found that:
1) High dietary levels of LA promoted CRC by increasing phosphatidylinositol 3-phosphate (PI3P) containing LA (PI3P_LA), which increases LRP5 membranous recycling and subsequently B-catenin activation.
2) ALOX15-induced conversion of PI3P_LA to PI3P_13-HODE suppresses LRP5 membranous recycling, B-catenin activation, CRC stemness, and LA promotion of CRC, especially formation of large tumors associated with CRC invasiveness.
3) ALOX15 loss of function (LOF) promotes large CRC tumor formation by azoxymethane in 12/15LOX-KO-12LOX (ALOX15-LOF) mice.
Whether loss of ALOX15 expression promotes CRC invasiveness remains unknown. Our preliminary data show that ALOX15-LOF mice increased CRC invasiveness and targeted APC mutation into LGR5+ colorectal stem cells induced CRC in the mice, which was blocked by transgenic ALOX15 expression. We therefore hypothesize that ALOX15 loss of function promotes CRC invasiveness by increasing PI3P_LA levels, which enhances LRP5 membranous recycling, thus potentiating Wnt/B-catenin signaling and subsequently stemness.
Aim 1 will determine the effects of ALOX15 gain of function and ALOX15 LOF on LRP5, B-catenin activation, CRC stemness, and invasiveness using CRC mouse models in which CRC invasiveness is promoted by either a combination of APC, KRASG12D, and TRP53R172H mutations or TRP53R172H mutation with AOM-induced B-catenin and KRAS mutations.
Aim 2 will determine the effects of ALOX15 LOF on PI3P-LA, LRP5, B-catenin activation, stemness, and invasiveness in human CRCs and examine the effects of ALOX15 re-expression via lentivirus Tet-On inducible system in human CRC-derived organoids on invasiveness in vitro and in vivo studies.
The proposed studies are expected to provide important mechanistic insights into whether colonic ALOX15 expression as a host factor affects CRC invasiveness risk, especially with high dietary LA intake. This gained knowledge could inform subjects with colorectal ALOX15 LOF to avoid high LA intake and spur development of interventions to target ALOX15 for re-expression to prevent invasive CRC.
Colorectal cancer (CRC) is the third leading cause of cancer deaths in the United States. The long-term goal of our research is to develop novel interventions to prevent colorectal carcinogenesis (CRC). CRC invasiveness, a critical adverse step during CRC progression, requires a combination of certain genetic mutations (e.g. APC, KRAS, and TRP53 mutations), which are the key events to drive CRC. However, CRC progression also requires additional factors which increase aberrant beta-catenin (B-catenin) activation above levels induced by APC/B-catenin mutations.
Linoleic acid (LA), the most commonly consumed omega-6 polyunsaturated fatty acid in humans, increases both chemically (AOM)- and APC mutation-induced CRC tumorigenesis in mice. Nonetheless, human studies have been inconclusive regarding the impact of dietary LA on CRC. Determination of LA's role in CRC is important because American diets are enriched with LA while expression of the main metabolizing enzyme for LA, 15-lipoxygenase-1 (ALOX15), is lost in human CRC.
Recently, we found that:
1) High dietary levels of LA promoted CRC by increasing phosphatidylinositol 3-phosphate (PI3P) containing LA (PI3P_LA), which increases LRP5 membranous recycling and subsequently B-catenin activation.
2) ALOX15-induced conversion of PI3P_LA to PI3P_13-HODE suppresses LRP5 membranous recycling, B-catenin activation, CRC stemness, and LA promotion of CRC, especially formation of large tumors associated with CRC invasiveness.
3) ALOX15 loss of function (LOF) promotes large CRC tumor formation by azoxymethane in 12/15LOX-KO-12LOX (ALOX15-LOF) mice.
Whether loss of ALOX15 expression promotes CRC invasiveness remains unknown. Our preliminary data show that ALOX15-LOF mice increased CRC invasiveness and targeted APC mutation into LGR5+ colorectal stem cells induced CRC in the mice, which was blocked by transgenic ALOX15 expression. We therefore hypothesize that ALOX15 loss of function promotes CRC invasiveness by increasing PI3P_LA levels, which enhances LRP5 membranous recycling, thus potentiating Wnt/B-catenin signaling and subsequently stemness.
Aim 1 will determine the effects of ALOX15 gain of function and ALOX15 LOF on LRP5, B-catenin activation, CRC stemness, and invasiveness using CRC mouse models in which CRC invasiveness is promoted by either a combination of APC, KRASG12D, and TRP53R172H mutations or TRP53R172H mutation with AOM-induced B-catenin and KRAS mutations.
Aim 2 will determine the effects of ALOX15 LOF on PI3P-LA, LRP5, B-catenin activation, stemness, and invasiveness in human CRCs and examine the effects of ALOX15 re-expression via lentivirus Tet-On inducible system in human CRC-derived organoids on invasiveness in vitro and in vivo studies.
The proposed studies are expected to provide important mechanistic insights into whether colonic ALOX15 expression as a host factor affects CRC invasiveness risk, especially with high dietary LA intake. This gained knowledge could inform subjects with colorectal ALOX15 LOF to avoid high LA intake and spur development of interventions to target ALOX15 for re-expression to prevent invasive CRC.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Ann Arbor,
Michigan
481091276
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been extended from 12/31/26 to 04/30/27 and the total obligations have increased 385% from $665,973 to $3,227,957.
Regents Of The University Of Michigan was awarded
ALOX15 Regulation in CRC Invasiveness via PI3P-LA Metabolism
Project Grant R01CA266223
worth $3,227,957
from National Cancer Institute in January 2021 with work to be completed primarily in Ann Arbor Michigan United States.
The grant
has a duration of 5 years 3 months and
was awarded through assistance program 93.393 Cancer Cause and Prevention Research.
The Project Grant was awarded through grant opportunity NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 5/21/26
Period of Performance
1/1/22
Start Date
4/30/27
End Date
Funding Split
$3.2M
Federal Obligation
$0.0
Non-Federal Obligation
$3.2M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for R01CA266223
Transaction History
Modifications to R01CA266223
Additional Detail
Award ID FAIN
R01CA266223
SAI Number
R01CA266223-1778013654
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NC00 NIH National Cancer Institute
Funding Office
75NC00 NIH National Cancer Institute
Awardee UEI
GNJ7BBP73WE9
Awardee CAGE
03399
Performance District
MI-06
Senators
Debbie Stabenow
Gary Peters
Gary Peters
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Cancer Institute, National Institutes of Health, Health and Human Services (075-0849) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,304,871 | 100% |
Modified: 5/21/26